skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Small-Molecule Inhibitor of FosA Expands Fosfomycin Activity to Multidrug-Resistant Gram-Negative Pathogens

Journal Article · · Antimicrobial Agents and Chemotherapy
DOI:https://doi.org/10.1128/aac.01524-18· OSTI ID:1497177
 [1];  [2];  [2];  [1];  [1];  [1];  [1];  [3];  [1];  [2];  [1]
  1. Univ. of Pittsburgh School of Medicine, PA (United States)
  2. Univ. of Maryland School of Medicine, Baltimore, MD (United States)
  3. Univ. of Maryland School of Pharmacy, Baltimore, MD (United States)

The spread of multidrug or extensively drug-resistant Gram-negative bacteria is a serious public health issue. There are too few new antibiotics in development to combat the threat of multidrug-resistant infections, and consequently the rate of increasing antibiotic resistance is outpacing the drug development process. This fundamentally threatens our ability to treat common infectious diseases. Fosfomycin (FOM) has an established track record of safety in humans and is highly active against Escherichia coli, including multidrug-resistant strains. However, many other Gram-negative pathogens, including the “priority pathogens” Klebsiella pneumoniae and Pseudomonas aeruginosa, are inherently resistant to FOM due to the chromosomal fosA gene, which directs expression of a metal-dependent glutathione S-transferase (FosA) that metabolizes FOM. Here, we describe the discovery and biochemical and structural characterization of ANY1 (3-bromo-6-[3-(3-bromo-2-oxo-1H-pyrazolo[1,5-a]pyrimidin-6-yl)-4-nitro-1H-pyrazol-5-yl]-1H-pyrazolo[1,5-a]pyrimidin-2-one), a small-molecule active-site inhibitor of FosA. Importantly, ANY1 potentiates FOM activity in representative Gram-negative pathogens. Collectively, our study outlines a new strategy to expand FOM activity to a broader spectrum of Gram-negative pathogens, including multidrug-resistant strains.

Research Organization:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
National Institutes of Health (NIH)
Grant/Contract Number:
R21AI123747; T32DK061296; TL1TR001858; T32AI095190
OSTI ID:
1497177
Journal Information:
Antimicrobial Agents and Chemotherapy, Vol. 63, Issue 3; ISSN 0066-4804
Publisher:
American Society for MicrobiologyCopyright Statement
Country of Publication:
United States
Language:
ENGLISH
Citation Metrics:
Cited by: 11 works
Citation information provided by
Web of Science

References (19)

Biological Costs and Mechanisms of Fosfomycin Resistance in Escherichia coli journal August 2003
Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation journal February 2010
The Mechanism of Action of Fosfomycin (Phosphonomycin) journal May 1974
Characterization of a Cys115 to Asp Substitution in the Escherichia coli Cell Wall Biosynthetic Enzyme UDP-GlcNAc Enolpyruvyl Transferase (MurA) That Confers Resistance to Inactivation by the Antibiotic Fosfomycin journal January 1996
Fosfomycin: Resurgence of an old companion journal May 2016
Fosfomycin Resistance Protein (FosA) Is a Manganese Metalloglutathione Transferase Related to Glyoxalase I and the Extradiol Dioxygenases journal March 1997
Functional Consequence of Covalent Reaction of Phosphoenolpyruvate with UDP- N -acetylglucosamine 1-Carboxyvinyltransferase (MurA) journal February 2012
Phosphonoformate:  A Minimal Transition State Analogue Inhibitor of the Fosfomycin Resistance Protein, FosA , journal November 2004
Fosfomycin Resistance in Escherichia coli , Pennsylvania, USA journal November 2015
Modeling of the Bacterial Growth Curve journal January 1990
Functional Analysis of Active Site Residues of the Fosfomycin Resistance Enzyme FosA from Pseudomonas aeruginosa journal March 2005
ESKAPEing the labyrinth of antibacterial discovery journal July 2015
Intravenous fosfomycin—back to the future. Systematic review and meta-analysis of the clinical literature journal June 2017
Predictive compound accumulation rules yield a broad-spectrum antibiotic journal May 2017
Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene journal August 2017
The Utility of Hydrogen/Deuterium Exchange Mass Spectrometry in Biopharmaceutical Comparability Studies journal June 2011
Inhibition of Fosfomycin Resistance Protein FosA by Phosphonoformate (Foscarnet) in Multidrug-Resistant Gram-Negative Pathogens journal October 2017
Structure and Dynamics of FosA-Mediated Fosfomycin Resistance in Klebsiella pneumoniae and Escherichia coli journal September 2017
Fosfomycin: Mechanism and Resistance journal January 2017